Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolLON:VEC
Previous Symbol
CUSIPN/A
Phone+44-1249-667700
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees478
Outstanding SharesN/A
Market Cap£0.00
OptionableOptionable
Vectura Group (LON:VEC) Frequently Asked Questions
What is Vectura Group's stock symbol?
Vectura Group trades on the London Stock Exchange (LON) under the ticker symbol "VEC."
What price target have analysts set for VEC?
8 brokerages have issued 1 year price objectives for Vectura Group's stock. Their forecasts range from GBX 78 to GBX 160. On average, they anticipate Vectura Group's stock price to reach GBX 124.88 in the next year. This suggests a possible upside of 73.6% from the stock's current price. View Analyst Price Targets for Vectura Group.
What is the consensus analysts' recommendation for Vectura Group?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vectura Group in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vectura Group.
Has Vectura Group been receiving favorable news coverage?
Headlines about VEC stock have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vectura Group earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Who are some of Vectura Group's key competitors?
Some companies that are related to Vectura Group include Allergy Therapeutics (AGY), Antisense Therapeutics (ANP), AstraZeneca (AZN), Avivagen (VIV), Bayer (BAYN), Bayer (BAYN), BEXIMCO PHARMAC/S GDR REGS (BXP), Cathay International (CTI), China Pharma (CPHI), Dechra Pharmaceuticals (DPH), Eco Animal Health Group (EAH), Futura Medical (FUM), GlaxoSmithKline (GSK), Hutchison China MediTech (HCM) and Mayne Pharma Group (MYX).
Who are Vectura Group's key executives?
Vectura Group's management team includes the folowing people:
- Mr. James Ward-Lilley, CEO & Exec. Director (Age 53)
- Mr. Paul Fry, CFO & Exec. Director
- Mr. Anthony Fitzpatrick, Exec. VP of Operations
- Elizabeth Knowles, Director of Investor Relations & Analysis
- Mr. John Murphy, Gen. Counsel & Company Sec. (Age 65)
How do I buy shares of Vectura Group?
Shares of VEC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Vectura Group's stock price today?
One share of VEC stock can currently be purchased for approximately GBX 71.95.
What is Vectura Group's official website?
How can I contact Vectura Group?
Vectura Group's mailing address is One Prospect West, CHIPPENHAM, SN14 6FH, United Kingdom. The company can be reached via phone at +44-1249-667700.
MarketBeat Community Rating for Vectura Group (LON VEC)
MarketBeat's community ratings are surveys of what our community members think about Vectura Group and other stocks. Vote "Outperform" if you believe VEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
